Abstract
With the wide use of combination antiretroviral therapy (cART), the life expectancy of HIV-infected individuals drastically improved. However, HIV infection and HIV-associated cancers were the most common causes of death in the HIV-infected populations. The HIV-associated cancers are divided into acquired immune deficiency syndrome (AIDS)-defining and non-AIDS-defining cancers based on the incidence among the HIV-infected patients. Among HIV-associated cancers, acquired immune deficiency syndrome-related lymphoma (ARL) is still the most common condition and the leading cause of HIV/AIDS-related deaths. Diffuse large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL) are the most common subtypes of the ARL. Although Hodgkin’s lymphoma (HL) is not considered as an AIDS-defining cancer, incidence of HL in HIV-infected individuals is higher than the general population. The review summarizes the new progress in the treatment of HIV-associated lymphoma.
Highlights
According to the 1993 revised classification system for human immunodeficiency virus (HIV) infection, HIV-associated cancers are divided into acquired immune deficiency syndrome (AIDS)defining and non-AIDS-defining cancers based on the coincidence among HIV-infected patients
Since 1996, with the wide use of combination antiretroviral therapies, the incidence of malignant cancers in people living with HIV (PLWHIV) has decreased significantly
The rituximab plus standard chemotherapy (R-CHOP) regimen chemotherapy only improved the complete response rate (CR) and did not result in a higher progression-free survival (PFS) and overall survival (OS) time in patients with the HIV-positive Diffuse large B-cell lymphoma (DLBCL) compared with the CHOP regime chemotherapy [20]
Summary
According to the 1993 revised classification system for human immunodeficiency virus (HIV) infection, HIV-associated cancers are divided into acquired immune deficiency syndrome (AIDS)defining and non-AIDS-defining cancers based on the coincidence among HIV-infected patients. DLBCL is the most common subtype of B-cell lymphoma or NHL in HIV-negative patients [3]. Since 1996, with the wide use of cART, the incidence of NHL declined to 1.8 per 1000 person-years in 2002-2006 [4, 5]. Before the cART, the DLBCL and primary central nervous system lymphoma (PCNSL) were the most common cancers, with an incidence of 4.53 and 2.33 per 1000 person-years, respectively. The DLBCL and BL were the most common cancers, with an incidence of 1.20 and 0.32 per 1000 person-years, respectively [6, 7]. Several other studies have shown that the most common subtypes of the ARL is the DLBCL, followed by BL [9,10,11,12,13,14]. The review focuses on the progress in the treatment of the above-mentioned HIVassociated lymphoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
